Joanna M. Biernacka

This study performs a trans-ancestry GWAS of SSRI response in depression, finding suggestive associations and enrichment in serotonergic pathways but no genome-wide significant variants.

The paper identifies novel CNV loci and dose-dependent gene effects across six psychiatric disorders using genome-wide analysis.

The paper identifies shared and divergent genetic mechanisms across psychiatric disorders using gene-set burden analysis of copy number variants.

The paper develops pathway-specific polygenic scores to predict lithium treatment response in bipolar disorder and finds associations with specific biological pathways.

The paper identifies FNDC4 as a gene associated with alcohol use disorder through GWAS and shows its role in regulating neurogenesis via alternative splicing and CRISPR/Cas9 experiments.

This study integrates genotype, epigenome, and phenotype data to show immune cells contribute to bipolar disorder pathogenesis, heterogeneity, and therapy through epigenomic and genetic mechanisms.

The paper identifies five genomic factors explaining most genetic variance across 14 psychiatric disorders and finds shared and disorder-specific genetic signals with distinct biological functions.

The paper examines the association between insomnia genetic liability and substance use disorders in bipolar disorder patients using polygenic risk scores and electronic health records.

This study examines the association between CYP2C19 and CYP2D6 metabolic phenotypes and antidepressant response using genotype imputation across 13 studies, finding no significant associations after correction for multiple testing.

This study performs a multi-ancestry meta-analysis of tobacco use disorder using electronic health records, identifying 88 risk loci and 461 potential risk genes, and linking TUD to various health outcomes.

The paper identifies three novel immune pathway genes with deleterious variants associated with Alzheimer's disease using polygenic risk scores in whole exome sequence data.

This study evaluates the association of genetic risk scores with depression and anxiety diagnoses, finding distinct genetic contributions to their comorbidity.

This study identifies genetic loci associated with suicide attempts and shows shared genetic architecture with psychiatric disorders and non-psychiatric risk factors.

This study identifies genetic variants associated with AUD treatment outcomes using pharmacogenomic analyses of naltrexone and acamprosate responses.

The paper identifies four genes, including two novel ones, co-expressed with TREM2 in Alzheimer's disease using whole-exome data from ADSP.

This paper introduces a principal component approach to improve association testing with polygenic risk scores by reducing type I error and improving power compared to permutation tests and a priori parameter selection.

This study conducts a trans-ancestral GWAS of alcohol dependence, identifying genetic variants and correlations with psychiatric disorders.

The paper shows that polygenic scores for depression traits predict lithium response in bipolar disorder patients, with lower genetic load linked to better treatment outcomes.

This study evaluates polygenic risk scores for MDD and neuroticism as predictors of antidepressant response across three cohorts, finding no significant prediction but consistent directional effects.

This paper conducts a GWAS on suicide attempt across psychiatric disorders, identifying genetic loci and showing polygenic risk for major depression predicts suicide attempt in multiple disorders.

This paper conducts a meta-analysis showing that CYP2C19 poor metabolizers have better antidepressant efficacy but similar side effects compared to extensive metabolizers.

This study identifies 114 genome-wide significant loci for schizophrenia and bipolar disorder, with specific subphenotype associations and four genes distinguishing the disorders.

This study identifies two SNPs associated with antidepressant response in GENDEP and STAR*D studies but finds limited replication in independent cohorts.

This study finds that a higher genetic risk for schizophrenia is linked to poorer lithium response in bipolar disorder patients, suggesting potential for personalized treatment strategies.